Masimo (MASI) Stock Price, News & Analysis

Company Overview

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

Key Stats

• Today's Range: $155.27 to $162.00
• 50-Day Range: $149.91 to $171.97
• 52-Week Range: $101.61 to $194.88
• Volume: 861,588 shs
• Average Volume: 497,009 shs
• Market Capitalization: $8.46 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $191.60
• Consensus Rating: Moderate Buy

Masimo Stock Analysis - MarketRank™

Masimo scored higher than 79% of companies evaluated by MarketBeat, and ranked 183rd out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Masimo has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Masimo has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 12.93%

Earnings Growth

Earnings for Masimo are expected to grow by 12.93% in the coming year, from $4.10 to $4.63 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Masimo is -17.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Masimo is -17.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Masimo has a P/B Ratio of 8.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.07% of the float of Masimo has been sold short.

Short Interest Ratio / Days to Cover

Masimo has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in Masimo has recently decreased by 7.62%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Masimo does not currently pay a dividend.

Dividend Growth

Masimo does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.86

Percentage of Shares Shorted

6.07% of the float of Masimo has been sold short.

Short Interest Ratio / Days to Cover

Masimo has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in Masimo has recently decreased by 7.62%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 1.09

News Sentiment

Masimo has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Masimo this week, compared to 10 articles on an average week.

Search Interest

Only 2 people have searched for MASI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Masimo to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Masimo insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,632,800.00 in company stock.

Percentage Held by Insiders

Only 9.70% of the stock of Masimo is held by insiders.

Percentage Held by Institutions

85.96% of the stock of Masimo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MASI Stock Analysis - Frequently Asked Questions

How have MASI shares performed this year?

Masimo's stock was trading at $165.30 on January 1st, 2025. Since then, MASI shares have decreased by 5.6% and is now trading at $156.02.

How were Masimo's earnings last quarter?

Masimo Corporation (NASDAQ:MASI) issued its quarterly earnings results on Tuesday, May, 6th. The medical equipment provider reported $1.36 EPS for the quarter, beating analysts' consensus estimates of $1.24 by $0.12. Masimo's revenue was down 24.5% on a year-over-year basis.
Read the conference call transcript.

Who are Masimo's major shareholders?

Masimo's top institutional shareholders include TD Asset Management Inc (0.31%), Swedbank AB (0.14%), Nordea Investment Management AB (0.06%) and Wilson Asset Management International PTY Ltd. (0.05%). Insiders that own company stock include Joe E Kiani, Bilal Muhsin and Craig B Reynolds.
View institutional ownership trends.

How do I buy shares of Masimo?

Shares of MASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Masimo own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Masimo investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/30/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:MASI
• CIK: 937556
• Web: www.masimo.com
• Phone: (949) 297-7000
• Fax: 949-297-7001
• Employees: 5,600
• Year Founded: 1989

Price Target and Rating

• Average Price Target for Masimo: $191.60
• High Price Target: $200.00
• Low Price Target: $185.00
• Potential Upside/Downside: +20.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 38.81
• P/E Growth: N/A
• Net Income: -$304.90 million
• Net Margins: -25.06%
• Pretax Margin: -14.11%
• Return on Equity: 22.56%
• Return on Assets: 10.00%

Debt

• Debt-to-Equity Ratio: 0.67
• Current Ratio: 2.17
• Quick Ratio: 1.62

Sales & Book Value

• Annual Sales: $2.13 billion
• Price / Sales: 4.06
• Cash Flow: $6.27 per share
• Price / Cash Flow: 25.39
• Book Value: $19.50 per share
• Price / Book: 8.16

Miscellaneous

• Outstanding Shares: 54,219,000
• Free Float: 45,056,000
• Market Cap: $8.63 billion
• Optionable: Optionable
• Beta: 1.19